Absci Corporation ABSI
Set alert
11.13 USD -0.97 -8.02%
At close · Oct 30
11.30 +0.17 +1.53%
After hours · Oct 30, 7:57 PM ET
10.45 Day range 11.80
2.30 52-week range 12.10
- YTD
- +218.91%
- 1 year
- +172.13%
- Open
- 11.41
- Prev close
- 12.10
- Mkt cap
- 1.91B
- Vol
- 4.57M
- Avg vol
- 3.53M
- EPS
- -0.79
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.45
- High
- 11.80
- Forward P/E
- -16.05
- Beta
- 2.28
- Short ratio
- 8.22
- Inst. own
- 87.33%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 9.47
- 200-d avg
- 6.45
- 1y target
- 14.82
MAX chart
Events in this range
- Aug 12, 2025Earnings: -0.24; estimate -0.19; surprise -26.32%
- Nov 12, 2025Earnings: -0.2; estimate -0.19; surprise -5.26%
- Mar 24, 2026Earnings: -0.23; estimate -0.16; surprise -43.75%
- May 7, 2026Earnings: -0.19; estimate -0.2; surprise 5%
- Aug 11, 2026Earnings: -0.18; estimate -0.19102; surprise 5.77%
- Sep 9, 2026Rating: LifeSci Capital · — → Outperform
- Sep 23, 2026Rating: Needham · Buy → Buy
- Oct 12, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 12, 2026Rating: JP Morgan · Overweight → Overweight
- Oct 16, 2026Rating: Keybanc · Overweight → Overweight
- Oct 29, 2026Rating: Jefferies · — → Buy
Signals (102)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 1 day ago |
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 5, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| RSI: Overbought | May 25, 2026 | 5 months ago |
| RSI: Overbought | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 18, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 20, 2025 | 1 year ago |
| SMA: Bullish | Jan 20, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 20, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| SMA: Bearish | Dec 16, 2024 | 1 year ago |
| SMA: Bullish | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| SMA: Bullish | Sep 16, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | Jun 10, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| RSI: Overbought | Feb 26, 2024 | 2 years ago |
| RSI: Overbought | Feb 12, 2024 | 2 years ago |
| RSI: Overbought | Jan 29, 2024 | 2 years ago |
| RSI: Overbought | Jan 8, 2024 | 2 years ago |
| RSI: Overbought | Dec 18, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 13, 2023 | 2 years ago |
| MACD: Sell Signal | Sep 25, 2023 | 3 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| SMA: Bearish | Sep 4, 2023 | 3 years ago |
| SMA: Bullish | Aug 28, 2023 | 3 years ago |
| SMA: Bullish | Aug 28, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jun 26, 2023 | 3 years ago |
| SMA: Bullish | May 22, 2023 | 3 years ago |
| MACD: Buy Signal | May 22, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 24, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 10, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 20, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 29, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 13, 2022 | 4 years ago |
| RSI: Oversold | Jun 6, 2022 | 4 years ago |
| MACD: Sell Signal | May 16, 2022 | 4 years ago |
| RSI: Oversold | May 9, 2022 | 4 years ago |
| SMA: Bearish | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 28, 2022 | 4 years ago |
| SMA: Bearish | Mar 21, 2022 | 4 years ago |
| SMA: Bullish | Feb 7, 2022 | 4 years ago |
| RSI: Oversold | Jan 3, 2022 | 4 years ago |
| SMA: Bearish | Nov 8, 2021 | 4 years ago |
| SMA: Bullish | Oct 25, 2021 | 5 years ago |
Key statistics
- Market cap
- 1.91B
- Enterprise value
- 1.88B
- Trailing P/E
- 0.00
- Forward P/E
- -16.05
- PEG ratio
- 0.00
- Price / sales
- 1223.62
- Price / book
- 7.76
- EPS (TTM)
- -0.79
- Beta
- 2.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.56M
- Revenue growth
- -46.40%
- Free cash flow
- -50.59M
- Total cash
- 201.14M
- Total debt
- 3.83M
- Return on equity
- -57.72%
- Shares outstanding
- 171.61M
- Short % of float
- 26.24%
- 50-day average
- 9.47
- 200-day average
- 6.45
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.82 +33.1% upside
Now 11.13
- Target (low)
- 10.00
- Target (mean)
- 14.82
- Target (high)
- 20.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.19763.
Financials — quick view
ABSI Revenue — quarterly 318.00K
ABSI Net income — quarterly -33.21M
ABSI EPS — quarterly -0.21
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.19081 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.19102 | -0.18 | +0.01 | +5.77% |
| May 7, 2026 | Mar 31, 2026 | -0.20 | -0.19 | +0.01 | +5.00% |
| Mar 24, 2026 | Dec 31, 2025 | -0.16 | -0.23 | -0.07 | -43.75% |
| Nov 12, 2025 | Sep 30, 2025 | -0.19 | -0.20 | -0.01 | -5.26% |
| Aug 12, 2025 | Jun 30, 2025 | -0.19 | -0.24 | -0.05 | -26.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Jefferies | init | — | Buy |
| Oct 16, 2026 | Keybanc | main | Overweight | Overweight |
| Oct 12, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 12, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2026 | Needham | reit | Buy | Buy |
| Sep 9, 2026 | LifeSci Capital | init | — | Outperform |
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- absci.com
News
- Jefferies Initiates Coverage On Absci with Buy Rating, Announces Price Target of $14
- Absci to Participate in Upcoming Investor Conferences
- Keybanc Maintains Overweight on Absci, Raises Price Target to $20
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- HC Wainwright & Co. Reiterates Buy on Absci, Maintains $16 Price Target
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
- Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast
Your note
Sign in to keep a note on ABSI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEDRICK TODD | Officer | Stock Award(Grant) | Mar 1, 2026 | 216,942 |
| BUSCH ANDREAS | Officer | Purchase | Mar 11, 2026 | 421,446 |
| JONASSON ZACHARIAH | Chief Financial Officer | Stock Award(Grant) | Mar 1, 2026 | 499,783 |
| MCCLAIN SEAN | Chief Executive Officer | Stock Award(Grant) | Mar 1, 2026 | 8,715,450 |
| MCGINNIS KAREN K | Director | Stock Award(Grant) | Jun 3, 2026 | 48,420 |
| PANGALOS MENELAS N | Director | Stock Award(Grant) | Jun 3, 2026 | 242,408 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.81% | 25,410,048 | 282.81M | Jun 29, 2026 |
| ARK Investment Management, LLC | 7.53% | 12,925,271 | 143.86M | Jun 29, 2026 |
| Blackrock Inc. | 7.09% | 12,175,302 | 135.51M | Jun 29, 2026 |
| State Street Corporation | 4.72% | 8,097,308 | 90.12M | Jun 29, 2026 |
| Ameriprise Financial, Inc. | 4.07% | 6,991,763 | 77.82M | Jun 29, 2026 |
| Redmile Group, LLC | 3.93% | 6,739,675 | 75.01M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 6.17% | 10,581,097 | 117.77M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.68% | 8,022,967 | 89.30M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.88% | 4,946,402 | 55.05M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.57% | 4,407,685 | 49.06M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.27% | 3,888,889 | 43.28M | Sep 29, 2026 |
| Columbia Acorn Trust-Columbia Acorn Fund | 1.68% | 2,889,066 | 32.16M | Jun 29, 2026 |